Help For Irritable Bowel Syndrome (IBS) - Education, Support, & Self Help for Irritable Bowel Syndrome
Heather & Company View Cart
Shop for IBSIBS Message BoardsIBS News & ReviewsStore Finder
Home
IBS Diet & Recipes
IBS Books
IBS Supplements
Yoga for IBS
Hypnosis for IBS
Tummy Teas
Get The IBS Diet Cheat Sheet
Get Trigger Foods, Safe Foods, Ten Commandments of Eating for IBS, More!

Enter First Name:

Enter Email:

We value your privacy


All Boards >> Irritable Bowel Syndrome Research Library

HeatherAdministrator

Reged: 12/09/02
Posts: 7677
Loc: Seattle, WA
FDA approves new drug for chronic constipation
01/26/17 03:05 PM

FDA approves new treatment for chronic constipation

January 20, 2017

Trulance received FDA approval for the treatment of chronic idiopathic constipation, according to press releases from the manufacturer and the FDA.

The impact of chronic constipation on the lives of affected patients is often underestimated, William D. Chey, MD, co-director of the Michigan Bowel Control Program at the University of Michigan and Healio Gastroenterology Peer Perspective Board member, said in a press release. Trulance presents an exciting new treatment option for patients with chronic constipation. Its efficacy and safety profile, plus its negligible systemic absorption, are attractive attributes that make it a welcome addition to our treatment options.

The FDA approved Trulance (plecanatide, Synergy Pharmaceuticals) at a 3-mg dose, taken orally once a day with or without food. The drug works in the upper GI tract to mimic uroguanylin and improve regular bowel function.

Approval came after two randomized, double blind, placebo-controlled clinical trials in which efficacy was studied in more than 2,600 patients and safety in more than 2,700. Patients were diagnosed with chronic idiopathic constipation (CIC) due to producing less than three spontaneous bowel movements (SBM) per week in the previous 3 months.

The efficacy responder rate defined as at least three complete SBM in a given week and at least one CSBM over baseline in the same week for at least 9 weeks was greater in both studies compared with placebo (21% vs. 10% and 21% vs. 13%; both P < .005). Those treated with plecanatide showed improvement in stool frequency, stool consistency and straining.

The FDA and manufacturer noted diarrhea as the most common adverse reaction (5% vs. 1% in placebo). Due to the risk for dehydration and lack of safety and efficacy data, the FDA said plecanatide should not be used in pediatric patients aged younger than 6 years and avoided from age 6 to age 18.

No one medication works for all patients suffering from chronic gastrointestinal disorders, Julie Beitz, MD, director of the Office of Drug Evaluation III in the FDAs Center for Drug Evaluation and Research, said in the FDA press release. With the availability of new therapies, patients and their doctors can select the most appropriate treatment for their condition.

Synergy Pharmaceuticals said the medication will be available for CIC patients in the U.S. this quarter. It is also being studied in IBS-C, according to the company. by Katrina Altersitz

Disclosures: Beitz is an employee of the FDA. Chey reports he is a consultant for Albreio, Allergan, Ardelyx, IM Health, Ironwood, Nestle, Prometheus, QOL Medical, Salix, Syn Biologic and Takeda, and has received grant or research support from Ironwood, Nestle, Perrigo and Prometheus.


http://www.healio.com/gastroenterology/motility/news/online/%7B7113d768-8a31-4238-b2bd-8b0a8af012cf%7D/fda-approves-new-treatment-for-chronic-constipation?utm_source=maestro&utm_medium=email&utm_campaign=gastroenterology%20news

--------------------
Heather is the Administrator of the IBS Message Boards. Shes the author of Eating for IBS and The First Year: IBS, and the CEO of Heather's Tummy Care. Join her IBS Newsletter. Meet Heather on Facebook!

Post Extras Print Post Remind Me! Notify Moderator

Entire thread
Subject Posted by Posted on
* Pharmaceutical HeatherAdministrator 07/14/03 01:50 PM
. * Long-term cannabis use increases risk for IBS HeatherAdministrator 10/19/17 04:04 PM
. * FDA approves new drug for chronic constipation HeatherAdministrator 01/26/17 03:05 PM
. * Mixed Opioid Agent Adds to Growing List of Therapies for IBS-D HeatherAdministrator 01/27/16 02:48 PM
. * Low-dose naltreoxone for the treatment of irritable bowel syndrome HeatherAdministrator 01/26/16 01:20 PM
. * Amitiza benefited patients with chronic idiopathic constipation HeatherAdministrator 02/10/15 04:15 PM
. * Medical Marijuana for Digestive Disorders: High Time to Prescribe? HeatherAdministrator 09/17/14 02:08 PM
. * Antibiotics Early in Life May Boost Obesity Risk HeatherAdministrator 08/18/14 03:13 PM
. *